Cui Kai, Zhang Senlin, Du Yueke, Chai Yutan, Liang Mingchu, Hu Shaoyan, Li Jie
Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, China.
Department of Nephrology and Immunology, Children's Hospital of Soochow University, Suzhou, China.
Front Immunol. 2025 Mar 25;16:1552263. doi: 10.3389/fimmu.2025.1552263. eCollection 2025.
Anti-thymocyte globulin (ATG) is frequently administered for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). In patients with low absolute lymphocyte count (ALC) before conditioning, weight-based dosing of ATG may cause overexposure, negatively impacting prognosis.
Clinical data of patients with hematological malignancies undergoing haploidentical HSCT (haplo-HSCT) at the Children's Hospital of Soochow University from January 2020 to June 2023 were collected. This study primarily aims to investigate the association between pre-conditioning ALC and clinical outcomes in pediatric acute leukemia or myelodysplastic syndromes patients receiving myeloablative haplo-HSCT.
We included 130 patients treated at the Children's Hospital of Soochow University from January 2020 to June 2023. According to the cutoff of 500/μl, patients were divided into high and low ALC groups. Patients in the high ALC group experienced a higher incidence of II-IV acute GVHD (30.2% versus 13.6%, = 0.034), 3-year overall survival (OS) and relapse-free survival (RFS) rates (OS: 88.5% ± 3.7% versus 66.9% ± 7.9%, = 0.013; RFS: 81.4% ± 4.1% versus 56.5% ± 8.1%, < 0.001), and lower cumulative incidence of relapse (11.3% versus 27.4%, = 0.013). Pre-conditioning ALC < 500/μl independently predicted worse OS, RFS, and higher relapse risk in multivariate analysis. However, there was no significant difference in immune reconstitution between the two groups.
Pre-conditioning ALC was a significant prognostic factor in pediatric patients undergoing myeloablative haplo-HSCT. Further research is needed to explore whether pre-conditioning ALC can serve as a reference for adjusting ATG dosing.
抗胸腺细胞球蛋白(ATG)常用于异基因造血干细胞移植(allo-HSCT)中预防移植物抗宿主病(GVHD)。在预处理前绝对淋巴细胞计数(ALC)较低的患者中,基于体重的ATG给药可能导致药物暴露过量,对预后产生负面影响。
收集2020年1月至2023年6月在苏州大学附属儿童医院接受单倍体造血干细胞移植(haplo-HSCT)的血液系统恶性肿瘤患者的临床资料。本研究主要旨在探讨接受清髓性haplo-HSCT的小儿急性白血病或骨髓增生异常综合征患者预处理前ALC与临床结局之间的关联。
我们纳入了2020年1月至2023年6月在苏州大学附属儿童医院接受治疗的130例患者。根据500/μl的临界值,患者被分为ALC高分组和低分组。ALC高分组患者II-IV级急性GVHD的发生率更高(30.2%对13.6%,P = 0.034),3年总生存率(OS)和无复发生存率(RFS)更高(OS:88.5%±3.7%对66.9%±7.9%,P = 0.013;RFS:81.4%±4.1%对56.5%±8.1%,P < 0.001),复发累积发生率更低(11.3%对27.4%,P = 0.013)。在多变量分析中,预处理前ALC < 500/μl独立预测OS、RFS更差且复发风险更高。然而,两组之间的免疫重建无显著差异。
预处理前ALC是接受清髓性haplo-HSCT的小儿患者的一个重要预后因素。需要进一步研究探索预处理前ALC是否可作为调整ATG剂量的参考依据